🏛️ Verified NIH Record • Updated 2026-06-29
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) (NCT05329649)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Vertex Pharmaceuticals Incorporated
🩺 Plain-English Summary (8th-Grade Level)
This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Who can join: Review the eligibility criteria below.
Location: Levine Children's Hospital - Hematology — Charlotte, North Carolina
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Levine Children's Hospital - Hematology — Charlotte, North Carolina
- The Children's Hospital of Philadelphia - Hematology — Philadelphia, Pennsylvania
- St. Jude Children's Research Hospital — Memphis, Tennessee
- TriStar Medical Group Children's Specialists - Pediatric Oncology — Nashville, Tennessee
- University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology — Düsseldorf,
- IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica — Rome,
- St.Mary's Hospital - Haematology Dept — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.